ReShape Lifesciences Inc
NASDAQ:RSLS
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| US |
|
ReShape Lifesciences Inc
NASDAQ:RSLS
|
1.2B USD |
Loading...
|
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
195.9B USD |
Loading...
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
172.5B USD |
Loading...
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
140B USD |
Loading...
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
127.5B USD |
Loading...
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
110.8B USD |
Loading...
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
46.4B EUR |
Loading...
|
|
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
50.3B USD |
Loading...
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
50.1B USD |
Loading...
|
|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
44.1B USD |
Loading...
|
|
| US |
|
Resmed Inc
NYSE:RMD
|
36.8B USD |
Loading...
|
Market Distribution
| Min | -24 813% |
| 30th Percentile | 28.9% |
| Median | 43% |
| 70th Percentile | 60.5% |
| Max | 10 905 714.3% |
Other Profitability Ratios
ReShape Lifesciences Inc
Glance View
ReShape Lifesciences, Inc. operates as a medical device company, which focuses on technology to treat obesity and metabolic diseases. The company is headquartered in San Clemente, California and currently employs 47 full-time employees. The company went IPO on 2016-10-06. The firm is focused on offering an integrated portfolio of products and services that manage and treat obesity and metabolic disease. Its Lap-Band and associated program provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures such as the gastric bypass or sleeve gastrectomy. The ReShape Vest System is an investigational minimally invasive, laparoscopically implanted medical device that wraps around the stomach, emulating the gastric volume reduction effect of conventional weight-loss surgery. The ReShapeCare Virtual health coaching program is a virtual telehealth weight management program that supports lifestyle changes for all weight-loss patients, to help them keep the weight off over time. The firm's Obalon Balloon System is intended for adults with a body mass index (BMI) of 30 to 40 kilograms/ square meter.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for ReShape Lifesciences Inc is 63.7%, which is above its 3-year median of 62.9%.
Over the last 3 years, ReShape Lifesciences Inc’s Gross Margin has increased from 56.9% to 63.7%. During this period, it reached a low of 54% on Sep 30, 2023 and a high of 68.2% on Sep 30, 2024.
